Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...

for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV. Abrysvo now offers the broadest ...

The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.

The US Food and Drug Administration (FDA) yesterday approved Abrysvo (respiratory syncytial virus vaccine). Developed and ...

The Food and Drug Administration (FDA) has approved Abrysvo ® (respiratory syncytial virus [RSV] vaccine) for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by ...

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

LSL PHARMA GROUP INC. ("LSL Pharma" or the "Corporation"), an integrated Canadian-based pharmaceutical company, reports that it will make on October 31, 2024, the first interest payment (the "Interest ...